PharmaEssentia and AOP Orphan Receive Positive CHMP Opinion For Besremi(™) (Ropeginterferon alfa-2b) For Treatment Of Polycythemia Vera (PV) In EU
WALTHAM, Mass., Dec. 17, 2018 /PRNewswire/ -- PharmaEssentia, a global biopharmaceutical company focused on developing and commercializing novel treatments for treatment of rare diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, r...
PharmaEssentia Updates Progress of Ropeginterferon Alfa-2b Clinical Program
WALTHAM, Mass., Dec. 5, 2018 /PRNewswire/ -- * 36 month analysis of ropeginterferon alfa-2b (Ropeg) phase III clinical data in Polycythemia Vera (PV) demonstrates superiority across three key aspects of disease control, including complete hematological response (CHR), disease burden, and molec...
PharmaEssentia Announces Favorable Two-year Results of Ropeginterferon Alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2017
WALTHAM, Mass., Dec. 11, 2017 /PRNewswire/ -- PharmaEssentia USA, a subsidiary of PharmaEssentia Corporation (Taipei Exchange: 6446), today announced the latest follow-up results of Ropeginterferon alfa-2b from the ongoing, long-term, follow-up trial CONTINUATION-PV (CONTI-PV) for patients with ...
